Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerRazelle Kurzrock, Ravi Salgia, John Frye et al.|Journal of Clinical Oncology|2011Cited by 551
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyRobert I. Haddad, Susan Darlow, Lindsay Bischoff et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 507
Conservation of the <i>Drosophila</i> lateral inhibition pathway in human lung cancer: A hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expressionHerbert Chen, Douglas W. Ball|Proceedings of the National Academy of Sciences|1997Cited by 269
Thyroid CarcinomaR. Michael Tuttle, Lori J. Wirth, Douglas W. Ball et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 205
Thyroid Carcinoma, Version 2.2014R. Michael Tuttle, Miranda Hughes, Robert I. Haddad et al.|Journal of the National Comprehensive Cancer Network|2014Cited by 200